

North Central Cancer Treatment Group

N0177: A Phase I/II Trial of OSI-774 and Temozolomide in Combination with Radiation Therapy in Glioblastoma Multiforme

Status Change – July 13, 2007

NOTICE OF STATUS CHANGE

Study 2 (EAC patients only) is re-opening to dose level 3ER (OSI-774 at 500 mg) for one more patient effective Friday, July 13, 2007.

Please retain this notice with the protocol.